Office use only PHQ-9 GAD-7 Global

õg @* x **

/
?ì ðW7Âû%XÐzzÅb)sf •gŠÃ\ WÔyZgzŠÆVà 2 ¸¦

: Zizg ã½ ÐyŠñŠ W yŠ F 7Ç!* <wEZ ó ó +¶

÷ ÷ nÆ䙄0 KÅ[Z LZ~ä{

PHQ-9
{Š c*
i
3 2 1 0 Xì CƒÙp c*
pŠ Á¹~ä™Ì¼ 1

3 2 1 0 X **
ƒyZ **
c*
{ŠfZÔ {Š%9, 2

3 2 1 0 X **
Î{Š c*
i¹c*
Ô **
ƒÂ~ gñÎc*
äÎ 3

3 2 1 0 X **
™kCð**
Z ÂÁ¹c*
**
™kCyÝ 4

3 2 1 0 X **
3{Š c*
i¹c*
¶~uÈ 5

3 2 1 0 LZ c*
Êpä\Wc* {g » **
\W tc*X **
™kCZ',0LZ 6

+{
Xì Hk-â ÃyZ0
3 2 1 0 X 9 Š ~zKc*
−7,
g ¶Z ‰Ô **
ƒÂ~ä™iÃ%z Â~x »Ë 7

3 2 1 0 X «Z »kZ c* h™kCvß}uzŠ&**
?¸M ™]!*
c*
•w3 W ÚZ 8

X ,™•w{Š c*
iÐw©\W **
™kCì"âZ
3 2 1 0 1Ðj§ËÊp c*
ì 4„**
Y%»\W **
W]ÑìÆnkZ 9

X OÎ~}g!*
Æäà

GAD-7
: Zizg ã½ ÐyŠñŠ W yŠ F 7Ç!* <wEZ ó ó +¶
÷ ÷ nÆ䙄0 KÅ[Z LZ~ä{
{Š c*
i

3 2 1 0 **
™kC'" c*
[sÔ !*
kZj 1

3 2 1 0 X **
0*
:1‡6,
kZ c*
**
™:È**
™„ 2

3 2 1 0 X **
™„{Š c*
i¹~}g!*
ÆVzqZ 3

3 2 1 0 X **
™kCÂ~äl 4

3 2 1 0 -Z **
XƒÂÎ(q ™kCu" ÚZ 5

3 2 1 0 X **
Yƒ×c*
nZg **
Ðã‚ W¹ 6

3 2 1 0 ì ÑZzäƒZ',
¼ **
™kCg et 7

?ì c* pg]©B‚ÆVÍß}uzŠ c*
¯ÂHÃp K6,b)Ñ!*
ÔÖÐwq‹gß~yÔä™x »Æ\ Wäb)yZ  ñÎy¶ /Z
{gÃèä\W¤
ì ¯Â{Š c*
iÐu ì c*
¯Â¹ ì c* -u¼
¯ÂJ ì c*
¯7ÂÇ!*

From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD PHQ). The PHQ was developed by Drs.
Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues. For research information, contact Dr. Spitzer at rls8@columbia.edu.
PRIME-MD® is a trademark of Pfizer Inc. Copyright© 1999 Pfizer Inc. All rights reserved. Reproduced with permission

TS35615/06 - Urdu